RAPP Expense Breakdown
Rapport Therapeutics, Inc. (RAPP). Quarter ended 2026-06-30 · each product line is listed as filed.
- 2026-06-30: RAP 219 Program External Expenses $34.09M; Research and Development Personnel Related Costs Including Stock-based Compensation $10.64M; Preclinical Programs External Expenses $4.87M; Other Costs $1.82M.
- 2025-06-30: RAP 219 Program External Expenses $9.69M; Research and Development Personnel Related Costs Including Stock-based Compensation $6.67M; Preclinical Programs External Expenses $4.72M; Other Costs $1.61M.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | RAP 219 Program External Expenses | Research and Development Personnel Related Costs Including Stock-based Compensation | Preclinical Programs External Expenses | Other Costs |
|---|---|---|---|---|
| 2026-06-30 | $34.09M | $10.64M | $4.87M | $1.82M |
| 2025-06-30 | $9.69M | $6.67M | $4.72M | $1.61M |
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | General and Administrative Personnel Related Costs Including Stock-based Compensation | Professional and Consulting Costs | Facility Related and Other |
|---|---|---|---|
| 2026-06-30 | $7.08M | $1.46M | $844.00K |
| 2025-06-30 | $5.04M | $920.00K | $851.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |